SEC Form 4
Natera, Inc. (NTRA) insider trading
In the 12 months to Oct 26, 2026, 11 NTRA insiders reported open-market sales of $331.3M across 76 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $331.3M
- 76 filings · 11 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 70 of 76
- $280.8M of $331.3M sold (85%)
Who traded NTRA, and when
- Sale
- Sale, pre-arranged (10b5-1)
NTRA daily close from Oct 27, 2025 to Oct 26, 2026, between $182.65 and $425.64, last $403.99. 76 sale and 0 purchase filings by 11 insiders, marked at their filing dates. Matthew Rabinowitz, EXECUTIVE CHAIRMAN: sold $140.0M across 9 filings, first filed Nov 3, 2025, last Oct 16, 2026. Steven Leonard Chapman, CEO AND PRESIDENT: sold $65.2M across 9 filings, first filed Nov 3, 2025, last Oct 2, 2026. Roelof Botha, Director: sold $34.9M across 2 filings, first filed Nov 26, 2025, last Jun 3, 2026. Jonathan Sheena, Director: sold $29.6M across 22 filings, first filed Nov 4, 2025, last Oct 23, 2026. Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER: sold $16.4M across 4 filings, first filed Mar 10, 2026, last Jul 6, 2026. Herm Rosenman, Director: sold $15.1M across 2 filings, first filed Dec 16, 2025, last Jun 26, 2026. 5 others: sold $30.1M across 28 filings, first filed Oct 29, 2025, last Oct 2, 2026.
Largest mark · tap a row for others
Matthew Rabinowitz · EXECUTIVE CHAIRMAN
Filing 1 of 2 within a week · $51,195,538 total
Sale $16,398,267
50,000 shares at $327.97 avg
Filed Sep 11, 2026
Pre-arranged (10b5-1) · close on filing date $328.93
Matthew Rabinowitz · EXECUTIVE CHAIRMAN
EXECUTIVE CHAIRMAN
$140.0M soldSteven Leonard Chapman · CEO AND PRESIDENT
CEO AND PRESIDENT
$65.2M soldRoelof Botha · Director
Director
$34.9M soldJonathan Sheena · Director
Director
$29.6M soldDaniel Rabinowitz · SEC. AND CHIEF LEGAL OFFICER
SEC. AND CHIEF LEGAL OFFICER
$16.4M soldHerm Rosenman · Director
Director
$15.1M sold5 others
Combined, one mark per week
$30.1M soldOpen-market trades
76 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN | $140.0M | — | 9 | 100% of sales | |
| Steven Leonard Chapman | CEO AND PRESIDENT | $65.2M | — | 9 | 100% of sales | |
| Roelof Botha | Director | $34.9M | — | 2 | — | |
| Jonathan Sheena | Director | $29.6M | — | 22 | 100% of sales | |
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | $16.4M | — | 4 | 100% of sales | |
| Herm Rosenman | Director | $15.1M | — | 2 | 27% of sales | |
| Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | $13.0M | — | 8 | 100% of sales | |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | $10.1M | — | 13 | 89% of sales | |
| Roy D. Baynes | Director | $2.8M | — | 1 | 100% of sales | |
| Gail Boxer Marcus | Director | $2.4M | — | 2 | 1% of sales | |
| Rowan E. Chapman | Director | $1.8M | — | 4 | 40% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,150 | $410.55 | $1.3M | 218,920 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $402.47 | $603.7K | Multiple accounts | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 50,000 | $402.64 | $20.1M | 2,147,047 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 1,273 | $413.31 | $526.1K | 96,926 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $414.22 | $1.2M | 109,714 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 18,064 | $388.01 | $7.0M | Multiple accounts | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 9,150 | $351.49 | $3.2M | 224,264 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 102,000 | $341.15 | $34.8M | Multiple accounts | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 50,000 | $327.97 | $16.4M | 2,225,394 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 1,698 | $320.99 | $545.0K | 98,199 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $320.73 | $962.2K | 126,619 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 6,000 | $325.32 | $2.0M | 230,464 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 2,000 | $320.90 | $641.8K | 2,000 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 9,150 | $315.66 | $2.9M | 236,953 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 478 | $274.22 | $131.1K | 51,637 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 1,894 | $265.40 | $502.7K | 99,897 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $265.25 | $795.8K | 130,572 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 3,041 | $251.11 | $763.6K | 52,432 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $273.88 | $410.8K | Multiple accounts | |
traded | Rowan E. Chapman Director | SalePre-arranged (10b5-1) | 135 | $274.82 | $37.1K | 4,663 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,150 | $265.68 | $836.9K | 246,202 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 1,000 | $280.00 | $280.0K | 4,000 | |
traded | Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | SalePre-arranged (10b5-1) | 16,800 | $272.29 | $4.6M | 177,994 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $272.90 | $818.7K | 137,543 | |
traded | Herm Rosenman Director | SalePre-arranged (10b5-1) | 16,530 | $250.00 | $4.1M | 4,250 | |
traded | Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | SalePre-arranged (10b5-1) | 33,600 | $251.65 | $8.5M | 200,224 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $219.87 | $329.8K | Multiple accounts | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,150 | $211.14 | $665.1K | 250,152 | |
traded | Rowan E. Chapman Director | SalePre-arranged (10b5-1) | 2,964 | $216.78 | $642.5K | 3,124 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 100,000 | $214.47 | $21.4M | 2,278,243 | |
traded | Gail Boxer Marcus Director | Sale | 11,000 | $217.21 | $2.4M | 6,183 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 41,124 | $221.03 | $9.1M | 108,743 | |
traded | Roelof Botha Director | Sale | 78,000 | $220.31 | $17.2M | 1,096,383 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $218.43 | $655.3K | 137,643 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 4,650 | $206.33 | $959.5K | Multiple accounts | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 482 | $210.49 | $101.5K | 57,496 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $203.36 | $610.1K | 144,735 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,071 | $196.42 | $603.2K | 255,711 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 3,070 | $193.74 | $594.8K | 58,491 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $199.63 | $299.4K | Multiple accounts | |
traded | Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | SalePre-arranged (10b5-1) | 8,400 | $203.31 | $1.7M | 226,794 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $202.30 | $606.9K | 148,834 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 4,570 | $198.75 | $908.3K | Multiple accounts | |
traded | Rowan E. Chapman Director | SalePre-arranged (10b5-1) | 122 | $191.38 | $23.3K | 5,752 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 200,000 | $191.42 | $38.3M | 2,360,672 | |
traded | Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER | SalePre-arranged (10b5-1) | 8,398 | $196.08 | $1.6M | 238,383 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,070 | $200.23 | $614.7K | 262,294 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 3,950 | $200.02 | $790.1K | 156,607 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $199.85 | $599.5K | 150,498 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 5,671 | $227.18 | $1.3M | 52,120 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 85,299 | $230.72 | $19.7M | 144,623 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $231.44 | $694.3K | 140,102 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 3,043 | $233.12 | $709.4K | 59,059 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $243.94 | $365.9K | Multiple accounts | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,070 | $234.45 | $719.8K | 264,078 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 36,573 | $242.67 | $8.9M | 64,123 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 3,848 | $229.08 | $881.5K | 138,202 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 2,951 | $228.95 | $675.6K | 125,158 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 1,500 | $225.94 | $338.9K | Multiple accounts | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 3,070 | $227.01 | $696.9K | 224,444 | |
traded | Herm Rosenman Director | Sale | 48,419 | $227.42 | $11.0M | 20,492 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sale | 4,692 | $230.76 | $1.1M | 113,065 | |
traded | Rowan E. Chapman Director | Sale | 4,366 | $243.10 | $1.1M | 5,777 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 4,400 | $238.07 | $1.0M | 143,422 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $238.15 | $714.5K | 109,061 | |
traded | Roelof Botha Director | Sale | 75,000 | $236.12 | $17.7M | 1,214,660 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 14,000 | $226.49 | $3.2M | Multiple accounts | |
traded | Roy D. Baynes Director | SalePre-arranged (10b5-1) | 12,780 | $219.85 | $2.8M | 18,359 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 4,570 | $197.61 | $903.1K | Multiple accounts | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 22,900 | $200.51 | $4.6M | 2,280,852 | |
traded | Jonathan Sheena Director | SalePre-arranged (10b5-1) | 4,000 | $200.07 | $800.3K | Multiple accounts | |
traded | Gail Boxer Marcus Director | SalePre-arranged (10b5-1) | 122 | $198.71 | $24.2K | 5,762 | |
traded | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | SalePre-arranged (10b5-1) | 3,000 | $198.60 | $595.8K | 112,061 | |
traded | Matthew Rabinowitz EXECUTIVE CHAIRMAN | SalePre-arranged (10b5-1) | 17,100 | $200.00 | $3.4M | 2,303,752 | |
traded | Steven Leonard Chapman CEO AND PRESIDENT | SalePre-arranged (10b5-1) | 160,703 | $199.96 | $32.1M | 303,304 | |
traded | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | SalePre-arranged (10b5-1) | 3,045 | $190.72 | $580.7K | 65,293 |
GET /stocks/filings/vX/form-4?tickers=NTRA&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NTRA"
],
"issuer_cik": "0001604821",
"owner_cik": "0001646649",
"accession_number": "0001646649-26-000035",
"form_type": "4",
"filing_date": "2026-10-23",
"period_of_report": "2026-10-21",
"issuer_name": "Natera, Inc.",
"issuer_trading_symbol": "NTRA",
"owner_name": "Sheena Jonathan",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 627,
"transaction_price_per_share": 409.8932,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 219525,
"transaction_value": 257003.03639999998,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025."
},
{
"id": "F3",
"description": "The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $409.22 to $410.03 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"NTRA"
],
"issuer_cik": "0001604821",
"owner_cik": "0001646649",
"accession_number": "0001646649-26-000035",
"form_type": "4",
"filing_date": "2026-10-23",
"period_of_report": "2026-10-21",
"issuer_name": "Natera, Inc.",
"issuer_trading_symbol": "NTRA",
"owner_name": "Sheena Jonathan",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 211,
"transaction_price_per_share": 412.1991,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 218709,
"transaction_value": 86974.0101,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025."
},
{
"id": "F5",
"description": "The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.00 to $412.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 190 records
- Option exercises25 records
- Tax withholding1 record
- Tax withholding (sold to cover)96 records
- Grants and awards63 records
- Gifts5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Natera, Inc.'s CEO sold stock?
Yes. Steven Leonard Chapman (CEO) sold 304,189 shares ($65.2M) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is NTRA’s insider data?
These are NTRA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track NTRA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NTRA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.